Genetic Basis and Therapies for Vascular Anomalies. Issue 1 (25th June 2021)

• Record Type: Journal Article
• Authors: Queisser, Angela; Seront, Emmanuel; Boon, Laurence M.; Vikkula, Miikka
• Is Part Of: Circulation research. Volume 129:Issue 1(2021)
• Page Start: 155
• Page End: 173
• Publication Date: 2021-06-25
• Subjects: endothelium -- mutation -- precision medicine -- sirolimus -- thalidomide; Cardiovascular system -- Periodicals; Blood -- Circulation -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; Sang -- Circulation -- Périodiques; Appareil cardiovasculaire -- Périodiques; 612.1
• DOI: 10.1161/CIRCRESAHA.121.318145
• Languages: English
• ISSNs: 0009-7330

Abstract

Abstract : Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin), RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERK (extracellular signal-regulated kinases), HGF (hepatocyte growth factor)/c-Met (hepatocyte growth factor receptor), and VEGF (vascular endothelial growth factor) A/VEGFR (vascular endothelial growth factor receptor) 2 cascades has led to the evaluation of tailored strategies with preexisting cancer drugs that interfere with these signaling pathways. The era of theranostics has started for the treatment of vascular anomalies. Registration: URL: https://www.clinicaltrialsregister.eu ; Unique identifier: 2015-001703-32.